News

Keep up to date with CTx announcements, press releases and general news items

By CTxadmin
 • 
6 months ago

It is with a mix of sadness and gratitude that Cancer Therapeutics CRC (CTX) announces the resignation of Dr George Morstyn from the Board of Directors. George was appointed to the Board in 2008 and since then the organisation has benefited from the …
Read More

By CTxadmin
 • 
6 months ago

The Federal Health Minister, Greg Hunt, announced today, $25M of funding to CTx partner, WEHI, to boost Australia’s capacity to perform compound screening, the first stage along the path of producing new drugs. Compound screening has been one of the bottlenecks in the complicated and lengthy …
Read More

By CTxadmin
 • 
6 months ago

Cancer Therapeutics CRC (CTX) is pleased to announce the appointment of Dr Brendon Monahan as Chief Scientific Officer. Brendon will succeed Dr Ian Street who was co-founder of CTX in 2007, and who will continue to provide services to the organisation in an advisory capacity. …
Read More

By CTxadmin
 • 
9 months ago

Melbourne-headquartered Cancer Therapeutics CRC (CTx) today announced a two-year research collaboration and a license agreement with Pfizer Inc. (NYSE: PFE). Under the terms of the agreement, Pfizer will gain the rights to two novel pre-clinical cancer programs and CTx will receive US$14.2 million [AUD$20M] upfront …
Read More

By CTxadmin
 • 
9 months ago

Mark is the founder and CEO of Medicines Development for Global Health, a small Melbourne based not-for-profit drug development company. Passionately focused on developing drugs for diseases with high unmet need he has led his organisation from the licensing of moxidectin, an abandoned drug development …
Read More

By CTxadmin
 • 
11 months ago

Of the 129 children enrolled in the trial from across Australia with high-risk and relapsed cancers, 67% were provided with personalised treatment plans aimed at killing their unique cancer cells. For most children enrolled in the trial, there were otherwise few to no treatment options …
Read More